TITLE

Feasibility of targeted next-generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia

AUTHOR(S)
Mansouri, L; Sutton, L-A; Ljungström, V; Sörqvist, E F; Gunnarsson, R; Smedby, K E; Juliusson, G; Stamatopoulos, K; Nilsson, M; Rosenquist, R
PUB. DATE
March 2014
SOURCE
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p694
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study which examines the presence of mutations in ATM and TP53 genes in chronic lymphocytic leukemia (CLL) using HaloPlex-targeted enrichment. A total of 124 CLL samples were studied according to the altered criteria shown by the International Workshop on CLL and demonstrated >70% tumor cells and typical immunophenotype. It reveals that 100% of the TP53 mutations and 13/14 of the ATM mutations were projected to be damaging using PolyPhen bioinformatics.
ACCESSION #
94762955

 

Related Articles

  • Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL. Halina, Antosz; Artur, Paterski; Barbara, Marzec-Kotarska; Joanna, Sajewicz; Anna, Dmoszyńska // Folia Histochemica et Cytobiologica;2010, Vol. 48 Issue 4, p534 

    B-cell chronic lymphocytic leukaemia (B-CLL) originates from B lymphocytes that may differ in the activation level, maturation state or cellular subgroups in peripheral blood. Tumour progression in CLL B cells seems to result in gradual accumulation of the clone of resting B lymphocytes in the...

  • 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Robak, T; Błoński, J Z; Urbańska-Ryś, H; Błasińska-Morawiec, M; Skotnicki, A B; Błoński, J Z; Urbańska-Ryś, H; Błasińska-Morawiec, M // Leukemia (08876924);Apr99, Vol. 13 Issue 4, p518 

    The aim of the study was to determine the effectiveness of 2-chlorodeoxyadenosine (2-CdA) administered in 2-h i.v. infusions in the treatment of B cell chronic lymphocytic leukemia (B-CLL) in patients 55 years old and younger. One hundred and thirteen patients received three to 10 courses of...

  • Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease. Hertlein, Erin; Beckwith, Kyle A.; Lozanski, Gerard; Chen, Timothy L.; Towns, William H.; Johnson, Amy J.; Lehman, Amy; Ruppert, Amy S.; Bolon, Brad; Andritsos, Leslie; Lozanski, Arletta; Rassenti, Laura; Zhao, Weiqiang; Jarvinen, Tiina M.; Senter, Leigha; Croce, Carlo M.; Symer, David E.; de la Chapelle, Albert; Heerema, Nyla A.; Byrd, John C. // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Studies of chronic lymphocytic leukemia (CLL) have yielded substantial progress, however a lack of immortalized cell lines representative of the primary disease has hampered a full understanding of disease pathogenesis and development of new treatments. Here we describe a novel CLL cell line...

  • Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. Lu Qian Wang; Yok Lam Kwong; Kit Fai Wong; Chi Shan Bonnie Kho; Dong Yan Jin; Eric Tse; Rosèn, Anders; Chor Sang Chim // Journal of Translational Medicine;2014, Vol. 12 Issue 1, p1 

    Background TP53 mutation/deletion is uncommon in chronic lymphocytic leukemia (CLL). We postulated that components of TP53-centered tumor suppressor network, miR-34b/c, in addition to DAPK1 and miR-34a might be inactivated by DNA hypermethylation. Moreover, we tested if miR-34b/c methylation...

  • Clinico-pathological impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: Experience from India. Amare, P. S. Kadam; Gadage, V.; Jain, H.; Nikalje, S.; Manju, S.; Mittal, N.; Gujral, S.; Nair, R. // Indian Journal of Cancer;Jul-Sep2013, Vol. 50 Issue 3, p261 

    BACKGROUND: The present study of 238 B-cell Chronic Lymphocytic Leukemia (B-CLL) patients were undertaken to seek the prevalence and to evaluate clinico-pathological significance of recurrent genetic abnormalities such as del(13q14.3), trisomy 12, del(11q22.3) (ATM), TP53 deletion, del(6q21) and...

  • Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Thornton, Patrick D.; Gruszka-Westwood, Alicja M.; Hamoudi, Rifat A.; Atkinson, Shayne; Kaczmarek, Pawel; Morilla, Ricardo M.; Hilditch, Benjamin L.; A'Hern, Roger; Matutes, Estella; Catovsky, Daniel // Hematology Journal;2004, Vol. 5 Issue 1, p47 

    Abnormalities of TP53 in chronic lymphocytic leukaemia (CLL) correlate with aggressive disease and transformation. We studied 115 patients with CLL including 90 untreated, 25 with heavily pretreated/refractory CLL using fluorescent in situ hybridisation (FISH) to detect allelic loss at...

  • CLL: Biology.  // Hematology Journal;2004 Supplement 2, Vol. 5, pS137 

    Presents abstracts of studies on chronic lymphocytic leukemia, focusing on biological aspects. Recognition of MIC-A and ULBP3 by VD1 T cells in B-CLL: Implications for anti-cancer surveillance; PRAME antigen is frequently expressed in lymphoproliferative diseases; P53 expression in chronic...

  • ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Pospisilova, S; Gonzalez, D; Malcikova, J; Trbusek, M; Rossi, D; Kater, A P; Cymbalista, F; Eichhorst, B; Hallek, M; Döhner, H; Hillmen, P; van Oers, M; Gribben, J; Ghia, P; Montserrat, E; Stilgenbauer, S; Zenz, T // Leukemia (08876924);Jul2012, Vol. 26 Issue 7, p1458 

    Recent evidence suggests that - in addition to 17p deletion - TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data from retrospective analyses and prospective clinical trials show that ∼5% of untreated CLL patients with treatment indication have a...

  • Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Lin, K; Rockliffe, N; Johnson, G G; Sherrington, P D; Pettitt, A R // Oncogene;4/10/2008, Vol. 27 Issue 17, p2445 

    In chronic lymphocytic leukaemia (CLL), mutation/deletion of TP53 is strongly associated with early disease progression, resistance to chemotherapy and short patient survival. Consequently, there is a pressing need to develop novel treatment protocols for this high-risk patient group. The...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics